Effective Targeted Chemoprophylaxis of Recurrent Liver Echinococcosis with Haplotype CYP1A2F1*A/A: a Clinical Case

Background. One of the main long­term quality criteria for treatment and prevention of echinococcosis is postoperative relapse, which rate varies widely within 3–54% between medical facilities. The genetic traits of recurrent liver echinococcosis comprise an important subject of research into its etiopathogenetic factors for  an effective prognosis of cyst relapse and treatment personalisation.

Materials and methods. Bashkir State Medical University (Ufa, Russia) provided facilities to study targeted  chemoprophylaxis efficacy in a case of relapsed liver echinococcosis with haplotype CYP1A2F1*A/A (AA) and the  UM phenotype of ultrarapid albendazole sulfoxide­to­albendazole sulfone metaboliser.

Results and discussion. The clinical case presented illustrates the rationale behind personalised  chemoprevention of recurrent echinococcosis with albendazole based on genotyping data. Genotyping allows  detection of an ultrafast metaboliser haplotype in blood implicating a rapid degradation of administered albendazole, reduced antiparasitic impact of drug therapy and more feasible relapse, in contrast with a normal metaboliser phenotype.

Conclusion. A successful secondary prevention of relapsed echinococcosis suggests the efficacy of personalising  albendazole­based chemoprophylaxis of recurrent echinococcosis with genotyping data.

1. Canali M., Aragrande M., Angheben A., Capelli G., Drigo M., Gobbi F., et al. Epidemiologic-economic models and the One Health paradigm: echinococcosis and leishmaniasis, case studies in Veneto region, Northeastern Italy. One Health. 2019;9:100115. DOI: 10.1016/j.onehlt.2019.100115

2. Aydin M.F., Adigüzel E. Evaluation of cystic echinococcosis cases in terms of sociodemographic, clinical and hospitalization features in Karaman Province, Turkey. Iran J Public Health. 2019;48(12):2232–9. PMID: 31993392

3. Khan A., Ahmed H., Naz K., Gul S., Ishaque M., Zaidi S.S.A., et al. Surgically confirmed cases of cystic echinococcosis from Baluchistan Province, Pakistan for the years 2011-2018. Acta Trop. 2020:105354. DOI: 10.1016/j.actatropica.2020.105354

4. Conraths F.J., Probst C., Possenti A., Boufana B., Saulle R., La Torre G., et al. Potential risk factors associated with human alveolar echinococcosis: Systematic review and meta-analysis. PLoS Negl Trop Dis. 2017;11(7):e0005801. DOI: 10.1371/journal.pntd.0005801

5. Avilov O.V. Principle and modules of the step-by-step risk assessment for non-communicable diseases. Healthcare, education and security. 2019;(1):97–105 (In Russ.).

6. Ryan E.T. Antiparasitic agents. In: Long S., Prober Ch., Fischer M., editors. Principles and practice of pediatric infectious diseases. Elsevier; 2018.

7. Naseri M., Akbarzadeh A., Spotin A., Akbari N.A., Mahami-Oskouei M., Ahmadpour E. Scolicidal and apoptotic activities of albendazole sulfoxide and albendazole sulfoxide-loaded PLGA-PEG as a novel nanopolymeric particle against Echinococcus granulosus protoscoleces. Parasitol Res. 2016;115(12):4595–603. DOI: 10.1007/s00436-016-5250-8

8. Zyuz’kov G.N., Zhdanov V.V., Udut E.V., Miroshnichenko L.A., Polyakova T.Y., Stavrova L.A., et al. Strategy of pharmacological regulation of intracellular signal transduction in regeneration-competent cells. Bull Exp Biol Med. 2019;166(4):448–55. DOI: 10.1007/s10517-019-04370-x

9. Mousavi S.R., Samsami M., Fallah M., Zirakzadeh H. A retrospective survey of human hydatidosis based on hospital records during the period of 10 years. J Parasit Dis. 2012;36(1):7–9. DOI: 10.1007/s12639-011-0093-9

10. Du L., Lei L., Zhao X., He H., Chen E., Dong J., et al. The interaction of smoking with gene polymorphisms on four digestive cancers: a systematic review and meta-analysis. J Cancer. 2018;9(8):1506–17. DOI: 10.7150/jca.22797

11. Alvela-Suárez L., Velasco-Tirado V., Belhassen-Garcia M., Novo-Veleiro I., Pardo-Lledías J., Romero-Alegría A., et al. Safety of the combined use of praziquantel and albendazole in the treatment of human hydatid disease. Am J Trop Med Hyg. 2014;90(5):819–22. DOI: 10.4269/ajtmh.13-0059

12. Wen H., Vuitton L., Tuxun T., Li J., Vuitton D.A., Zhang W., et al. Echinococcosis: advances in the 21st Century. Clin Microbiol Rev. 2019;32(2):e00075-18. DOI: 10.1128/CMR.00075-18

13. Wan Z., Peng X., Ma L., Tian Q., Wu S., Li J., et al. Targeted sequencing of genomic repeat regions detects circulating cell-free echinococcus DNA. PLoS Negl Trop Dis. 2020;14(3):e0008147. DOI: 10.1371/journal.pntd.0008147

14. Chen X., Duan X., Shao Y., Jiang J., Zheng S., Wen H. Control of human echinococcosis in Xinjiang, China, with 2,544 surgeries in a multihospital network. Am J Trop Med Hyg. 2017;97(3):658–65. DOI: 10.4269/ajtmh.17-0052

15. Skuhala T., Trkulja V., Runje M., Balen-Topić M., Vukelić D., Desnica B. Combined albenazole-praziquantel treatment in recurrent brain echinococcosis: case report. Iran J Parasitol. 2019;14(3):492–6. PMID: 31673271